ID   SNU-1196
AC   CVCL_5015
SY   SNU1196
DR   ArrayExpress; E-MTAB-2770
DR   BioSample; SAMN10988072
DR   CCLE; SNU1196_BILIARY_TRACT
DR   Cell_Model_Passport; SIDM00163
DR   Cosmic; 738876
DR   Cosmic; 2674049
DR   DepMap; ACH-000461
DR   GEO; GSM887607
DR   GEO; GSM888690
DR   IARC_TP53; 17162
DR   KCLB; 01196
DR   LiGeA; CCLE_002
DR   PharmacoDB; SNU1196_1442_2019
DR   Wikidata; Q54955104
RX   CelloPub=CLPUB00275;
RX   PubMed=12107841;
RX   PubMed=19956504;
RX   PubMed=22460905;
RX   PubMed=27231123;
RX   PubMed=30894373;
RX   PubMed=31068700;
CC   Part of: Cancer Cell Line Encyclopedia (CCLE) project.
CC   Part of: Seoul National University (SNU) cell line collection.
CC   Doubling time: 48 hours (PubMed=12107841).
CC   Sequence variation: Homozygous for TP53 p.Arg273Cys (c.817C>T) (PubMed=12107841; CCLE).
CC   Omics: Deep exome analysis.
CC   Omics: Deep RNAseq analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis.
CC   Genome ancestry: African=0.3%; Native American=0%; East Asian, North=61.64%; East Asian, South=37.54%; South Asian=0%; European, North=0%; European, South=0.51% (PubMed=30894373).
ST   Source(s): KCLB
ST   Amelogenin: X
ST   CSF1PO: 10
ST   D13S317: 9
ST   D3S1358: 14,15
ST   D5S818: 11
ST   D7S820: 8,11
ST   FGA: 24,25
ST   TH01: 5,7
ST   TPOX: 10,11
ST   vWA: 14,16
DI   NCIt; C36077; Hilar cholangiocarcinoma
DI   ORDO; Orphanet_99978; Klatskin tumor
OX   NCBI_TaxID=9606; ! Homo sapiens
SX   Sex unspecified
AG   Age unspecified
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 12-03-20; Version: 20
//
RX   CelloPub=CLPUB00275;
RA   Zach S., Birgin E., Ruckert F.;
RT   "Primary cholangiocellular carcinoma cell lines.";
RL   J. Stem Cell Res. Transplant. 2:1013-1013(2015).
//
RX   PubMed=12107841; DOI=10.1038/sj.bjc.6600440;
RA   Ku J.-L., Yoon K.-A., Kim I.-J., Kim W.-H., Jang J.-Y., Suh K.-S.,
RA   Kim S.-W., Park Y.-H., Hwang J.-H., Yoon Y.-B., Park J.-G.;
RT   "Establishment and characterisation of six human biliary tract cancer
RT   cell lines.";
RL   Br. J. Cancer 87:187-193(2002).
//
RX   PubMed=19956504; DOI=10.4143/crt.2005.37.1.1;
RA   Ku J.-L., Park J.-G.;
RT   "Biology of SNU cell lines.";
RL   Cancer Res. Treat. 37:1-19(2005).
//
RX   PubMed=22460905; DOI=10.1038/nature11003;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.K., Yu J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
//
RX   PubMed=27231123; DOI=10.1158/2159-8290.CD-15-1442;
RA   Saha S.K., Gordan J.D., Kleinstiver B.P., Vu P., Najem M.S., Yeo J.-C.,
RA   Shi L., Kato Y., Levin R.S., Webber J.T., Damon L.J., Egan R.K.,
RA   Greninger P., McDermott U., Garnett M.J., Jenkins R.L.,
RA   Rieger-Christ K.M., Sullivan T.B., Hezel A.F., Liss A.S., Mizukami Y.,
RA   Goyal L., Ferrone C.R., Zhu A.X., Joung J.K., Shokat K.M., Benes C.H.,
RA   Bardeesy N.;
RT   "Isocitrate dehydrogenase mutations confer dasatinib hypersensitivity
RT   and SRC dependence in intrahepatic cholangiocarcinoma.";
RL   Cancer Discov. 6:727-739(2016).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z., Monteiro A.N., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J., Gelfand E.T., Bielski C.M., Li H.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//